Ovarian Function Suppression is named as an intervention in 2 current clinical trials in our China, Canada, Mexico, Japan and Israel registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). The most-studied condition is HR+/HER2- Advanced Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 3 | Recruiting | NRG Oncology | Canada, Mexico, Japan, Israel |
|
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
NCT05983107 · ClinicalTrials.gov ↗ · HR+/HER2- Advanced Breast Cancer, Targeted Therapy
|
Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| NRG Oncology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Mexico | 1 | 1 |
| Clinical trials in Japan | 1 | 1 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, Canada, Mexico, Japan and Israel registers name Ovarian Function Suppression as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China, 1 with sites in Canada, 1 with sites in Mexico, 1 with sites in Japan and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) and NRG Oncology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ovarian Function Suppression works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ovarian Function Suppression works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ovarian Function Suppression (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.